COL18A1 and neoplasm: Endostar (recombinant human endostatin injection), a targeted drug against VEGF receptors, has been found to not only inhibit tumor angiogenesis, but also suppress the generation of tumor lymphatic vessels and lymphatic metastasis (Shang et al. 2014).